The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
The Center for Human Genetics and Laboratory Medicine's Prenatalis test is based on Illumina's Verifi technology.
Birmingham Women's NHS Foundation Trust said it is partnering with Illumina to develop an NIPT, which it hopes to start offering in September.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
Non-invasive prenatal screening tests are not only detecting fetal chromosomal abnormalities, but also some cases of maternal cancer.
The results are the most comprehensive picture so far of the patterns of abnormal NIPT results that could indicate a woman has a higher risk of carrying an unknown tumor.
The company's new clinical laboratory will provide interim and backup services for its customers.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.